Lab Monitoring
Schedule
When to Get Blood Work on GLP-1: Optimal Schedule
The recommended lab testing timeline for GLP-1 medication patients -- what to test and when.
Last updated: April 1, 2026-12 min read
Regular lab monitoring on GLP-1 medications serves two purposes: ensuring safety and documenting the remarkable metabolic improvements most patients experience. Here is the optimal testing schedule recommended by obesity medicine specialists.
Recommended Testing Schedule
Lab Testing Timeline
| Timepoint | Core Tests | Additional Tests |
|---|---|---|
| Baseline | CMP, lipids, HbA1c, TSH, CBC | Vit D, B12, liver panel, fasting insulin |
| 3 months | CMP, lipids, HbA1c | Liver function if abnormal at baseline |
| 6 months | CMP, lipids, HbA1c, TSH, CBC | Vit D, B12, nutrient panel, hormones |
| 12 months | Full panel repeat | Inflammatory markers, cardiac panel |
| Annually | Full panel repeat | Based on individual needs |
Why Regular Monitoring Matters
Benefits of Regular Lab Work
- Safety: Catch kidney, liver, or thyroid issues early
- Nutrition: Detect vitamin/mineral deficiencies from reduced food intake
- Motivation: See objective improvements in cholesterol, blood sugar, inflammation
- Medication adjustments: Reduce or eliminate diabetes/BP/cholesterol medications
- Documentation: Create a medical record of your health transformation
Special Monitoring Situations
- Retatrutide patients: More frequent liver function tests (monthly for first 3 months)
- Patients with diabetes: More frequent HbA1c and glucose monitoring
- Large weight loss (50+ lbs): Comprehensive nutrient panel every 3-6 months
- Patients over 60: Add bone density (DEXA) baseline and annually
- Cardiovascular risk: Add cardiac panel and inflammatory markers
Comprehensive Treatment with Monitoring
Trimi physicians recommend appropriate lab schedules for every patient. Semaglutide $99/mo. Tirzepatide $125/mo.
Get StartedMedical Disclaimer
Lab testing recommendations may vary based on individual medical history. Your healthcare provider will determine the appropriate monitoring schedule for your situation.
More on GLP-1 lab monitoring
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).